Pregnancy and naltrexone pharmacotherapy

Cresta W. Jones, Mishka Terplan

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


A 25-year-old woman, gravida 3 para 2 at 12 weeks of gestation, with two prior cesarean deliveries, presents for prenatal care. She is in treatment for opioid use disorder on extended-release naltrexone injection, with a history of opioid overdose, relapse, and poor treatment adherence on methadone and buprenorphine. She asks, "Is it safe for my baby if I continue on this medication? How will you manage my postoperative pain?"copy 2018 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.

Original languageEnglish (US)
Pages (from-to)923-925
Number of pages3
JournalObstetrics and gynecology
Issue number4
StatePublished - 2018


Dive into the research topics of 'Pregnancy and naltrexone pharmacotherapy'. Together they form a unique fingerprint.

Cite this